Tvardi Therapeutics (TVRD) Research & Development (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Research & Development of $4.9 million for Q1 2026, down 10.56% sequentially from $5.5 million in Q4 2025, and up 57.86% YoY from $3.1 million in Q1 2025.
Tvardi Therapeutics (TVRD) Research & Development (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Research & Development for 14 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Research & Development rose 57.86% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (down 14.01% YoY) and the FY2025 annual result came in at $18.0 million, down 23.84% from the prior year.
- Research & Development declined to $4.9 million in Q1 2026 per TVRD's latest filing, from $5.5 million in the prior quarter.
- Over five years, Research & Development peaked at $30.3 million in Q2 2023 and troughed at $3.1 million in Q1 2025.
- A 5-year average of $15.6 million and a median of $19.9 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 59.15% in 2022, then sank 85.84% in 2025.
- Over 5 years, Research & Development stood at $26.0 million in 2022, then gained by 9.25% to $28.4 million in 2023, then tumbled by 69.72% to $8.6 million in 2024, then tumbled by 36.17% to $5.5 million in 2025, then fell by 10.56% to $4.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.9 million, $5.5 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.91 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 5.81 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 8.60 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 6.53 Mn |
| Mar 31, 2024 | 21.96 Mn |
| Dec 31, 2023 | 28.42 Mn |
| Sep 30, 2023 | 25.45 Mn |
| Jun 30, 2023 | 30.31 Mn |
| Mar 31, 2023 | 24.33 Mn |
| Dec 31, 2022 | 26.01 Mn |
| Sep 30, 2022 | 24.69 Mn |
| Jun 30, 2022 | 19.91 Mn |
| Mar 31, 2022 | 21.27 Mn |
| Dec 31, 2021 | 22.83 Mn |
| Sep 30, 2021 | 15.51 Mn |
| Jun 30, 2021 | 25.23 Mn |